PETALUMA, Calif., Nov 08, 2007 (BUSINESS WIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) today announced that financial results for the 2008 fiscal second quarter ended September 30, 2007, will be released before the U.S. market open on November 12, 2007.
The earnings release will be followed by a conference call at 8:30 a.m. PT (11:30 a.m. ET) on November 12, 2007, to discuss 2008 fiscal second quarter corporate highlights and financial results.
A live audiocast over the Internet will be available at http://ir.oculusis.com/events.cfm. Please log on approximately 30 minutes prior to the presentation in order to register and download any necessary software. The webcast will be available for one year at this website.
To listen over the phone, please call 1-877-407-4018 (domestic/toll-free) or 1-201-689-8471 (international). A telephone replay will be available for 30 days after the call at 1-877-660-6853 (domestic/toll-free), or 1-201-612-7415 (international). Please enter account number 3055 and conference identification number 261781.
Oculus Innovative Sciences is a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, which is intended to help prevent and treat infections in chronic and acute wounds. The Microcyn Technology platform is a controlled slow-release solution containing active chlorine and other gases resulting in a biocompatible technology to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria, viruses, fungi and spores. The technology has demonstrated significant wound healing in chronic and acute wounds. It has been commercialized outside of the U.S. for the treatment of infected wounds. It is currently under evaluation for the treatment of mildly infected diabetic ulcers in the U.S.
Oculus' principal operations are in Petaluma, California, and it conducts operations in Europe, Latin America and Japan through its wholly owned subsidiaries, Oculus Innovative Sciences Netherlands B.V., Oculus Technologies of Mexico, S.A. de C.V. and Oculus Japan K.K. Oculus' website is www.oculusis.com.
Oculus, Microcyn®, and Dermacyn® are trademarks or registered trademarks of Oculus Innovative Sciences, Inc. All other trademarks and services marks are the property of their respective owners.
SOURCE: Oculus Innovative Sciences, Inc.
Oculus Innovative Sciences, Inc. Director of Public and Investor Relations Dan McFadden, 425-753-2105 firstname.lastname@example.org or Investors: The Ruth Group Sara Ephraim, 646-536-7002 email@example.com or Media: Jason Rando / Janine McCargo, 646-536-7025 / 7033 firstname.lastname@example.org email@example.com
Copyright Business Wire 2007
News Provided by COMTEX